Dr. med. Dipl. biol. Bernd Löffler

Creator and founder of ageLine®

After years of practice and research at renowned institutions such as the Max Planck Institute for Experimental Medicine and Hoffmann-La-Roche, Dr. Bernd Löffler founded the Institute for Preventive & Aesthetic Medicine in 2005 and later the Institute for Mitochondrial Medicine.

Here he and his Team are researching how aging processes of patients can be decelerated based on state-of-the-art medical expertise, e.g. using mitochondrial medicine, dealing with the energy and metabolic processes of cells, including skin aging.



Development of medications


Major part in development of 2 medications:

  1. Tracleer (Bosentan) for PAH (pulmonary arterial hypertension)

  2. SPP301 for diabetic nephropathy (Fast Track status granted in December 2006)


77 publications, 50 international patents, more than 200 lectures and congress papers

Expert activities

DFG, ÖFG, Hypertension, FEBS

Member of

  • Society of German Chemists

  • German Society of Biochemistry and Molecular Biology

  • Forum Orthomolecular Medicine

  • German Society of Preventive Medicine

  • German Society for Anti-Ageing Medicine

  • American Association for Anti-Ageing Medicine

  • American Heart Association

  • American Diabetes Association

Dr. Löffler’s research approach


“It was always my intension to go to the bottom of things and understand the processes at the core to able to change them fundamentally. This is also my approach in research and development – to seek the origin of the problem and its solution.
This was the only way to develop products that achieve a truly new level of effectiveness.”


1975 – 1985

Studies of Human Medicine, Biology, Chemistry and Physics at the Georg-August-University Göttingen


Diploma in Biology, Focus on biochemistry with Summa cum Laude



Doctorate in medicine with Summa cum Laude


1978 – 1980

Scientific assistant at the Institute of Plant Biochemistry, University of Göttingen Deputy Head PD Dr. Harnischfeger


1980 – 1984

Scientific assistant at the Max Planck Institute for Experimental Medicine, Research Group Prof. Dr. H. Kunze, Department Prof. Dr. W. Vogt


1985 – 1989

Scientific researcher at the Max Planck Institute for Experimental Medicine, Research Group Prof. Dr. H. Kunze, Department Prof. Dr. W. Vogt



Guest professor at the University of Edmonton, Canada, working group Prof. Dr. D.N. Brindley


1989 – 2005

Preclinical research F. Hoffmann-La Roche (Basel) since 2002 in the function of a Vice-Director


2003 – 2004

Education in men’s medical care at HOMMAGE




Since 2004

Continuous education in Orthomolecular and Preventive Medicine


April 2005

Founding of Löffler Consulting in Zug (Switzerland), scientific advice for research-based pharmaceutical companies (e.g. F. Hoffmann-La Roche, Santhera, Biovitrum)


May 2005

Founding IPAM (Institute for Prevention and Antiaging Medicine)
Development of medical products, lectures, preventive medical education


December 2006

Summoned in the Scientific Advisory Board of Santhera Pharmaceuticals AG


February 2007

Private practice for preventive medicine (formerly Platz vor dem neuen Tor 5, 10115 Berlin, enlargement of practice rooms from 01.02.2007 in Knesebeckstrasse 68/69, 10623 Berlin)


Since December 2006

Member of the Scientific Advisory Board of Santhera Pharmaceuticals

Research focus: testosterone biosynthesis regulation, lysosomal phospholipid metabolism, renin-angiotensin system, endothelin system, dipeptidyl peptidase IV


1989 – 2000

Cardiovascular disease, SAH (subarachnoid hemorrhage)


2000 – 2005

Metabolic disorders (Main focus: type II diabetes, metabolic syndrome)